Adaptive Biotechnologies Statistics
Share Statistics
Adaptive Biotechnologies has 151.92M
shares outstanding. The number of shares has increased by 0.82%
in one year.
| Shares Outstanding | 151.92M |
| Shares Change (YoY) | 0.82% |
| Shares Change (QoQ) | 0.68% |
| Owned by Institutions (%) | 97.08% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 298 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 9.1M, so 5.99% of the outstanding
shares have been sold short.
| Short Interest | 9.1M |
| Short % of Shares Out | 5.99% |
| Short % of Float | 7.68% |
| Short Ratio (days to cover) | 2.52 |
Valuation Ratios
The PE ratio is -5.53 and the forward
PE ratio is -14.35.
Adaptive Biotechnologies's PEG ratio is
0.18.
| PE Ratio | -5.53 |
| Forward PE | -14.35 |
| PS Ratio | 4.93 |
| Forward PS | 4 |
| PB Ratio | 4.35 |
| P/FCF Ratio | -8.93 |
| PEG Ratio | 0.18 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Adaptive Biotechnologies.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.89,
with a Debt / Equity ratio of 0.44.
| Current Ratio | 2.89 |
| Quick Ratio | 2.81 |
| Debt / Equity | 0.44 |
| Debt / EBITDA | -0.69 |
| Debt / FCF | -0.9 |
| Interest Coverage | -14.04 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $289,106.62 |
| Profits Per Employee | $-257,660.74 |
| Employee Count | 619 |
| Asset Turnover | 0.33 |
| Inventory Turnover | 8.54 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by 175.65% in the
last 52 weeks. The beta is 1.76, so Adaptive Biotechnologies's
price volatility has been higher than the market average.
| Beta | 1.76 |
| 52-Week Price Change | 175.65% |
| 50-Day Moving Average | 8.32 |
| 200-Day Moving Average | 6.6 |
| Relative Strength Index (RSI) | 60.15 |
| Average Volume (20 Days) | 2,326,167 |
Income Statement
In the last 12 months, Adaptive Biotechnologies had revenue of 178.96M
and earned -159.49M
in profits. Earnings per share was -1.08.
| Revenue | 178.96M |
| Gross Profit | 106.88M |
| Operating Income | -162.55M |
| Net Income | -159.49M |
| EBITDA | -128.76M |
| EBIT | -148.01M |
| Earnings Per Share (EPS) | -1.08 |
Full Income StatementBalance Sheet
The company has 47.92M in cash and 89.39M in
debt, giving a net cash position of -41.47M.
| Cash & Cash Equivalents | 47.92M |
| Total Debt | 89.39M |
| Net Cash | -41.47M |
| Retained Earnings | -1.3B |
| Total Assets | 510.85M |
| Working Capital | 168.68M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -95.21M
and capital expenditures -3.66M, giving a free cash flow of -98.88M.
| Operating Cash Flow | -95.21M |
| Capital Expenditures | -3.66M |
| Free Cash Flow | -98.88M |
| FCF Per Share | -0.67 |
Full Cash Flow StatementMargins
Gross margin is 59.72%, with operating and profit margins of -90.83% and -89.12%.
| Gross Margin | 59.72% |
| Operating Margin | -90.83% |
| Pretax Margin | -89.18% |
| Profit Margin | -89.12% |
| EBITDA Margin | -71.95% |
| EBIT Margin | -90.83% |
| FCF Margin | -55.25% |
